The supplied joint guideline treats physical dependence as a pharmacological adaptation that is distinct from a substance-use diagnosis.
ASAM and nine partner organizations developed the document through literature review, modified GRADE methods, and clinical consensus. It emphasizes ongoing risk-benefit review, shared decisions, individualized tapering, response-based adjustments, and psychosocial support. It advises against abrupt discontinuation in people likely to be physically dependent and at withdrawal risk.
The publication combines evidence-informed recommendations with consensus where evidence is limited. It is guidance for clinical judgment, not a trial proving one schedule best for every patient. This article describes the supplied edition rather than asserting the status of every later revision.
For chart review, withdrawal after regular treatment does not alone establish addiction or misuse. Examine the indication, duration, clinical adaptation, taper decisions, and patient response. A generic schedule cannot replace individualized assessment, particularly when seizure risk, psychiatric illness, or concurrent drugs complicate discontinuation.
Source reviewed: Joint Clinical Practice Guideline on Benzodiazepine Tapering Considerations When Risks Outweigh Bene (PMC12463801). This article summarizes the supplied paper; forensic applications above are interpretive analysis.
Related reading: A Portuguese Benzodiazepine-Dependence Questionnaire Was Validated in a Selected Population; Benzodiazepine Dose and ICU Restraints: Interpreting a Two-Way Clinical Relationship.